Results 181 to 190 of about 165,540 (296)
Clinical Outcomes of Children With Autoimmune Hepatitis in Korea: A Nationwide Multicenter Study. [PDF]
Ahn JE +16 more
europepmc +1 more source
Summary Follicular lymphoma (FL) first‐line chemoimmunotherapy yields high efficacy but serious toxicity in 65% of patients. In high tumour burden treatment‐naïve FL, we aimed to exploit known immunostimulatory and cytotoxic properties of combination checkpoint inhibition (atezolizumab) and obinutuzumab (6 cycles) with positron emission tomography (PET)
Arina Martynchyk +15 more
wiley +1 more source
Performance evaluation of mainstream large language models in autoimmune hepatitis patient education: a comparative study of readability, quality, and reliability. [PDF]
Li H, Lin Y, Lv L.
europepmc +1 more source
Assessment of central blood volume in cirrhosis by radionuclide angiography [PDF]
Bendtsen, Flemming +10 more
core
Summary T‐cell abnormalities have been implicated in the pathogenesis of acquired pure red cell aplasia (PRCA), particularly in its major subtypes such as idiopathic PRCA, thymoma‐associated PRCA and large granular lymphocytic leukaemia (LGLL)–associated PRCA, and the precise details remain unclear.
Naruaki Yamashita +11 more
wiley +1 more source
Comparative evaluation of immunoserological detection of F-actin antibodies. [PDF]
Dellbrügge F +5 more
europepmc +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Drug-induced autoimmune hepatitis due to atorvastatin: a complex clinical case and literature review. [PDF]
Serrano-Pérez NH +4 more
europepmc +1 more source

